Julia Chapman
Partner | Philadelphia
Julia Chapman

Julia Chapman is a litigator who represents clients in antitrust, competition, and commercial litigation matters. She handles complex cases through all stages of litigation, from early dispositive motions through class certification proceedings through trial. Ms. Chapman has a track record of developing creative arguments for early-stage dismissal and uses her antitrust trial experience to drive strategy and factual development from day-one of every case. Ms. Chapman also counsels clients on antitrust compliance and represents clients in investigations by the FTC and DOJ Antitrust Division.

Ms. Chapman is also committed to her pro bono civil rights practice. She has represented various state conferences of the NAACP in challenges to restrictive voting laws around the country and has led settlement negotiations that resulted in restored and expanded access to the right to vote. Ms. Chapman also regularly represents incarcerated and formerly incarcerated individuals in civil rights actions, appeals and resentencing proceedings.

In 2023 Law360 recognized Ms. Chapman as a “Rising Star” in the Competition/Antitrust practice area. Each year, the publication names those it judges to be the world’s top legal talent under the age of 40. Previously, Ms. Chapman received the “Best of the Bar” award from Philadelphia Business Journal. Who’s Who Legal currently recognizes her as a “Future Leader,” she is “Recommended” by Legal 500 USA and listed in Best Lawyers among the “Ones to Watch” for Antitrust Law.

  • CareFirst of Maryland v. Johnson & Johnson (E.D.Va.). Representing Johnson & Johnson in defense monopolization claims related to the monoclonal antibody Stelara.
  • Crowder v. LinkedIn (N.D. Cal.). Representing LinkedIn in defense of a monopolization claim brought by a putative class of premium subscribers.
  • United States v. Google Inc. (D.D.C.). Representing Microsoft as a third-party in the Department of Justice’s antitrust action challenging Google’s alleged monopolization of the search market.
  • GEHA v. Actelion Pharmaceuticals (D. Md.). Representing Janssen Pharmaceuticals and subsidiaries in defense monopolization claims claiming delayed entry of generic of Actelion’s Tracleer product.
  • In re Opana ER Antitrust Litigation (N.D. Ill.). Represented Endo Pharmaceuticals in its defense of class actions based on an alleged “reverse payment” patent litigation settlement. Secured complete defense verdict after four-week trial in federal court in Chicago.
  • In re Generic Pharmaceutical Pricing Antitrust Litigation. (E.D. Pa.). Defending a generic pharmaceutical company in multi-district litigation, brought by private plaintiffs and state attorneys generals, involving an alleged price fixing and supply reduction conspiracy.
  • In re Caustic Soda Antitrust Litigation (W.D.N.Y.). Defending a large chemical manufacturer in class action cases brought by direct and indirect purchasers claiming it participated in a price-fixing and supply reduction conspiracy in the caustic soda market. Secured complete dismissal of parent company in 2019. In 2023, Julia successfully argued in opposition to the Direct Purchaser Plaintiffs’ motion for class certification.
  • FTC v. Endo Pharmaceuticals (D.D.C.). Represented Endo Pharmaceuticals in novel action brought by Federal Trade Commission challenging a patent licensing agreement. Secured dismissal of all claims with prejudice; dismissal was unanimously affirmed by the D.C. Circuit Court.
  • Dana Farber Cancer Inst. v. Bristol-Meyers Squibb (D. Mass.). Represented Dana Farber in unfair competition claims related to inventorship of six immunology patents. The case resolved prior to trial.
  • Mish International Monetary v. Vega Capital London (N.D. Ill.). Representing 12 individual commodities futures traders against putative class claims under the Sherman Antitrust Act and the Commodities Exchange Act based on trading of West Texas Intermediate Crude Oil futures contracts.
  • FTC v. Meta (D.D.C.). Representing technology company as a non-party in the Federal Trade Commission’s antitrust action against Meta.
  • In re Amitiza Antitrust Litigation (D. Mass.). Represented a generic pharmaceutical company in defense of claims brought on behalf of direct purchasers challenging an alleged “reverse payment” patent litigation settlement.
  • In re Colcrys Antitrust Litigation (E.D. Pa.). Represented a generic pharmaceutical company in defense of alleged horizontal conspiracy claims arising out of resolution of patent infringement litigations.
  • In re Processed Eggs Antitrust Litigation (E.D. Pa.). Served as trial counsel for a defendant national egg producer in a six-week federal antitrust jury trial in which plaintiffs alleged a supply reduction and price fixing conspiracy. Secured complete defense verdict.
  • In re Urethanes Antitrust Litigation (D.N.J.). Represented Dow Chemical Company in a four-week antitrust trial on price fixing claims brought by opt-out plaintiffs. The case settled favorably prior to verdict.
  • In re Southeast Milk Antitrust Litigation (E.D. Tenn.). Represented a national milk processor trial counsel against claims of price-fixing by a large supermarket chain and a convenience store owner, resulting in a favorable settlement.
  • IMN v. Fresenius (S.D. Ind.). Represented a leading dialysis services provider against claims of monopolization, attempted monopolization, and various state law contract and tort claims based on allegedly exclusionary conduct in the dialysis market. Secured dismissal of all antitrust claims.
  • Genus Life Sciences v. Lannett (N.D. Cal.). Represented a national pharmaceutical company in defense of antitrust and false advertising claims based on its product marketing. Secured dismissal with prejudice of all antitrust claims.
  • Highmark Inc. v. U.S. Health Group (E.D. Pa.). Represented a health insurance company as plaintiff in civil RICO, fraud, and civil conspiracy litigation. Reached favorable settlement.
  • In 2023 Law360 recognized Ms. Chapman as a “Rising Star – Competition/Antitrust.”
  • In 2022, Philadelphia Business Journal named Ms. Chapman among the “2022 Best of the Bar.”
  • In 2023, Ms. Chapman was once again listed in The Legal 500 U.S. guide where it was noted she “is well-versed in all stages of litigation particularly in the life sciences, specialty chemicals and tech fields.”
  • In 2022, Ms. Chapman was once again recognized in Who’s Who Legal as a “Future Leader – Competition.”
  • In 2021, Best Lawyers recognized Ms. Chapman as being among the “Ones To Watch” for Antitrust Law in Pennsylvania. This recognition is given to attorneys who are early on in their careers for outstanding professional excellence based off of peer review.
  • In 2019, The Legal Intelligencer named Ms. Chapman among Pennsylvania’s “Lawyers on the Fast Track” in its 2019 Professional Excellence Awards.
  • In 2018, Global Competition Review named Ms. Chapman among the “Litigators of the Week” for achieving a decisive victory for family-owned Pennsylvania egg producer R.W. Sauder, Inc. in a US$1 billion antitrust class action jury trial in Philadelphia Federal Court.
  • Cartel Regulation 2022, U.S. Chapter - (December 16, 2021)
  • Cartel Regulation 2020, U.S. Chapter - (February 14, 2020)
  • The US District Court for the Eastern District of Pennsylvania Finds That a Company was not Part of a Conspiracy to Manipulate the Supply of Eggs and Raise Prices - (September 01, 2018)
    • Pennsylvania State University, B.A., 2009, With Honors
    • Georgetown University Law Center, J.D., 2013, cum laude, Editor-in-Chief of the Annual Survey of White Collar Crime, a publication of the American Criminal Law Review
    • Pennsylvania
    • United States Court of Appeals for the Third Circuit
    • United States Court of Appeals for the District of Columbia Circuit
    • United States District Court for the Eastern District of Pennsylvania
    • United States District Court for the Middle District of Pennsylvania
    • United States District Court for the Northern District of Illinois
    • Young Lawyer Representative, ABA Section of Antitrust Law’s Advertising Disputes and Litigation Committee (2018-2019)
    • Member, Board of Directors, Pennsylvania Court Appointed Special Advocates (2018-2021)
    • Investigative Team Member, Philadelphia Bar Association’s Commission on Judicial Selection (2019-present)
    • United States District Court for the Eastern District of Pennsylvania, Honorable Mary A. McLaughlin